NASDAQ · Biotechnology

Curis, Inc. (CRIS) Stock

$0.71 -0.42% NASDAQ: CRIS Healthcare

Valuation

MetricValue
Price$0.71
Market Cap$1.38M
P/E Ratio-0.06
P/B Ratio0.36
P/S Ratio0.36
EPS (TTM)$0.00
52-Week High$34.40
52-Week Low$0.68
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-693.93%
ROA-111.51%
ROCE-679.00%
Gross Margin99.45%
Operating Margin-4.85%
Net Margin-490.33%
Debt/Equity0.22
Current Ratio0.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$10.0M$10.0M$11.0M$9.0M
Operating Profit$-42.0M$-53.0M$-48.0M$-45.0M$-33.0M
Net Profit$-45.0M$-57.0M$-47.0M$-43.0M$-8.0M
EPS$-198.40$-242.80$-179.20$-137.60$-11.60
Op Margin-395.0%-521.8%-482.2%-408.3%-348.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$162.0M$109.0M$77.0M$41.0M$20.0M
Total Liabilities$72.0M$62.0M$58.0M$47.0M$15.0M
Cash$40.0M$20.0M$27.0M$20.0M$5.0M
Borrowings$5.0M$4.0M$3.0M$3.0M$2.0M

Latest News

Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia MT Newswires · Jul 6, 2026 Curis Consents First Six Patients in TakeAim CLL Study PR Newswire · Jul 6, 2026 Curis opens 11 sites for emavusertib combo in TakeAim CLL trial Clinical Trials Arena · Jun 29, 2026 BC-Most Active Stocks Associated Press · Jun 26, 2026 Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split PR Newswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-38.0M$-54.0M$-38.0M$-40.0M$-27.0M
Investing Cash Flow$-48.0M$33.0M$38.0M$29.0M$3.0M
Financing Cash Flow$-4.0M$0$-7.0M$0$0
Net Cash Flow$-90.0M$-20.0M$7.0M$-7.0M$-15.0M
Free Cash Flow$-38.0M$-55.0M$-38.0M$-40.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.14
FCF Yield-1989.12%
Quick Ratio0.49
Interest Coverage-16.50
Return 1Y-87.15%
Return 3Y-98.52%
Return 5Y-99.84%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASBPAspire-Lakewood Holdings, Inc. $8.43 +1.51% -1.09 $972009 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
BCTXBriaCell Therapeutics Corp. $3.95 +0.77% -0.33 $34.36M 0.00%
CTXRCitius Pharmaceuticals, Inc. $0.49 -2.47% -0.25 $13.42M 0.00%
ENTOEntero Therapeutics, Inc. $2.85 -5.00% -0.82 $13.58M 0.00%

About Curis, Inc.

Curis, Inc. is led by CEO James E. Dentzer, employs 34 people, headquartered in US, publicly traded since 2000.

Curis, Inc. (CRIS) stock trades at $0.71 with a market capitalization of $1.38M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.36, price-to-sales of 0.36. Over the past 52 weeks the stock has ranged between $0.68 and $34.40, and currently trades 97.9% below its 52-week high.

On profitability, Curis, Inc. generates a return on equity (ROE) of -693.93%, return on capital employed of -679.00%, an operating margin of -4.85%, a net profit margin of -490.33%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1171.57 +0.17% JNJ Johnson & Johnson $259.05 +1.00% ABBV AbbVie Inc. $275.98 +1.30% MRK Merck & Company, Inc. Common Stock (new) $144.50 +1.49% UNH UnitedHealth Group Incorporated Common Stock (DE) $375.98 +1.36% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $654.67 +0.41% AMGN Amgen Inc. $412.50 +1.24% GILD Gilead Sciences, Inc. $149.51 +1.64% ABT Abbott Laboratories $99.93 +1.46% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides